

Jeffrey B. Blumberg, PhD, FASN, FACN



Affiliations: Dr. Blumberg is a Professor in the Friedman School of Nutrition Science and Policy and also serves as a Senior Scientist in the Antioxidants Research Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.

Disclosures: He serves on the scientific advisory boards of AdvoCare, Cranberry Institute/Cranberry Marketing Committee, Herbalife, Pfizer Consumer Healthcare, Pharmavite, Quaker Oats and SmartyPants.



Knowing is not enough; we must apply Willing is not enough; we must do.

- Johann Wolfgang von Goethe (1749-1832)

IOM FNB. DRI Cover page 2000

.

Hill's Criteria of Causation

The Environment and Disease: Association or Causation?

- Consistency of association
- · Specificity of association
- Strength of association
- Experimental evidence
- Plausibility
- · Temporality
- · Biological gradient
- Coherence
- Analogy



RCTs, Observational Studies and the Hierarchy of Research Designs

The popular belief that only randomized, controlled trials produce trustworthy results and that all observational studies are misleading does a disservice to patient care, clinical investigation, and education of health care professionals.

Concato et al. N Engl J Med 2000

We found little evidence that estimates of treatment effects in observational studies reported after 1984 are either consistently larger than or qualitatively different from those obtained in randomized, controlled trials.

Benson and Hartz. N Engl J Med 2000

Evidence-Based Nutrition: RCTs as the "Gold Standard"

RCTs are given the greatest weight for evidence because they are the experimental design which best permits strong causal inference.

However, RCTs as implemented have limited generalizability and impose constraints ill-suited to testing of nutrients.

Revised Hierarchy of Evidence-based Nutrition



RCTs for Drugs vs. Nutrients:
Control Group

- Drugs: drug-free state (placebo)
- Nutrients: "high" intake contrasted with "low" intake

RCTs for Drugs vs. Nutrients: Control Group


- Drugs: drug-free state (placebo)
- Nutrients: "high" intake contrasted with "low" intake


Induce nutrient insufficiency or deficiency



10

Vitamin D Insufficiency During Pregnancy





Whitehouse et al. Pediatrics 2012

Harvey et al. J Clin Endocrinol Metab 2014

Impact of Vitamin D Insufficiency During Pregnancy Requires RCTs

Randomized controlled trials of Vitamin D supplementation are required to verify these observational data that suggest that an adequate maternal vitamin D status during pregnancy is necessary for optimal language development in offspring.

- Whitehouse et al. Pediatrics 2012

Formal testing of this hypothesis in an interventional setting should be undertaken before the development of any clinical recommendations.

- Harvey et al. J Clin Endocrinol Metab 2014

Impact of Vitamin D Insufficiency During Pregnancy Requires RCTs

Randomized controlled trials of Vitamin D supplementation are required to verify these observational data that suggest that an adequate maternal vitamin D status during pregnancy is necessary for optimal language development in offspring.

- White I wants 2012
UNFEASIBLE!

Formal testing of this hypothesis in an intervacional setting should be undertaken before the development of any clinical recommendations.

- Harvey et al. J Clin Endocrinol Metab 2014

13

Healthy Aging as Outcome Criteria SU.VI.MAX 2


DCT

- n, 3996
- age, $65.3 \pm 4.5 \text{ y}$
- intervention, 8 y
- F/U, 15 y

SUPPLEMENT

- Vitamin C, 120 mg
- Vitamin E, 30 mg
- β-carotene, 6 mg
- Selenium 100 μg
- Zinc, 20 mg

Assmann et al. Am J Epidemiol 2015



Antioxidant Supplementation as a Predictor of Healthy Aging


Stratification Variable	<u>Total n</u>	RR	<u>95% CI</u>	<u>P</u>
All participants	3996	1.07	0.99-1.16	
Men	2027	1.16	1.04-1.29	0.03
Women	1939	0.98	0.86-1.11	
Vitamin C status, <42 μmol/L	727	1.28	1.06-1.56	0.06
Zinc status, <11.9 μmol/L	953	1.26	1.06-1.49	0.05
F&V (<400 g/d)	1757	1.17	1.02-1.32	0.22

Assmann et al. Am J Epidemiol 2015

Is It Unethical or Infeasible to Restrict Intake of Foods Rich in Non-essential Bioactives?

United States China Mexico

Study Design for Acute Bioactive Intervention



Rodriguez-Mateos (University of Düsseldorf) 2015

RCTs for Drugs vs. Nutrients: Effect Scope

• Drugs: principally target a single system

• Nutrients: usually pan-systemic

RCTs for Drugs vs. Nutrients: Effect Scope

- Drugs: principally target a single system
- Nutrients: usually pan-systemic

For example:

- Statins inhibit HMG-CoA reductase
- 200
- Zinc is a cofactor for >100 enzymes and plays a role in protein structure and gene expression



19

(Poly)phenol Mechanisms of Action


Modulation of:

- Signal transduction pathways
- · Transcription factors
- DNA acylation/methylation
- Mitochondrial function
- Autophagy
- Plasma membrane proteins/phospholipids



Followers of the control of the cont

Cocoa Increases Flow-Mediated Dilation, Plasma Nitroso Species, and Total Flavanols



RCT XO: • n, 10 men

- age, 25-32 y
- · dose, 917 vs 37 mg cocoa flavanols

Schroeter et al. PNAS 2006

22

efsa: European Food Safety Authority

Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Natrition and Allergies (NDA)2.7

Cocoa flavanols help maintain endothelium-dependent vasodilation, which contributes to normal blood flow. In order to obtain the claimed effect, 200 mg of cocoa flavanols should be consumed daily. This amount could be provided by 2.5 g of high-flavanol cocoa powder or 10 g of high-flavanol dark chocolate, both of which can be consumed in the context of a balanced diet. The target population is the general population.

Agostoni et al. EFSA J 2012

2

RCTs for Drugs vs. Nutrients: Effect Size

- Drugs: usually large and targeted
- Nutrients: usually modest but aggregated effect across multiple systems over time

RCTs for Drugs vs. Nutrients: Effect Size

- Drugs: usually large and targeted
- Nutrients: usually modest but aggregated effect across multiple systems over time

For example:

Negative Ca balance of 30 mg/d

- \rightarrow 10% loss of BMD/y
- → osteoporosis in 30 y




Croop Too Flavanals Lower Systolic Blood Prossura

	100	and the		14	ole was			Blass (Whoreson)	Major (IRRenance)
Mindy or Subgroup	Mone	100	10440	Mean	1421	Total	Weight	36, Ruselbers, 3971-04	N, Randess, White
Seanwisk 2012	-43	5.7	29	-4.6	1.8	29	10.0%	4.1014.31, 1106	Table State
Brief (20)	1440	1.19	43	41.36	17/18	42	9.7%	-2.50) E 86, 8 420	
December 2011	11.54	3.61	100	31.58	1.62	64	13.1%	0.30 (4.60, 2.26)	-
Dispress 2000E	6.3	IO SA	35	34	11.86	35	24%	- 281 (42), 163	
Frank 2008	- 1	100	- 48	- 4	19.5	75	1.1%	+1.85 +10.38, 9.26	
46L7567	604	0.01	19	11.79	2.41	14			
Hrs. 2006	-0.8	14.9	10	-2.0	12.2	32	27%	-0.70 (4.74, 5.36)	
New SELECTION	- 31	26.6	26	28	16.6	27	1.2%	P. SECTION, 18:275	
Hallmidt 2002	+0.1	16.4	- 10		15.6	200	1.1%	-8.36+05.77, 5.07	-
Malicanena 7088	2.3	16.54	- 31	7.8	1127	10	1.5%	8 80 130 47 1407	
Timpes 2007	427	13.0	1133	0.8061	12	1.17	1.0%	-4,70 (5.84, 6.54)	
Yeiges 7009	16.0	1/1 (80)	179	4.8	HEAT	200	1.4%	18,300,200,337,8-272	
Harts 2008	- 0	- 4	95	0.0001	6.2	79	110.2%	-2.60 (4.24 - 4.71)	
Serie 2011	E-1898Y	17.8	- 36	0.000%	11.0	25	1.79		
Dultternikos 2013	42.57	1.0	15	14.20	1.82	200	1.0%		-
Tabasa 2288		112	41	- 4	13	8.00	1194	0.00 (0.30, 1.70)	
Takesmin (2008)	-4	103	43	-4	18	39	1.0%	0.00340.44, 4.44	
WEIWERS 2007	- 10	0.0	- 11		- 31	#	110	3.00313.00,12.00	
Tokal (1975) Cit			180			662	100.01	1041285-000	•
Helenga tests: Tw/	OUT ON	0-164		17/2-1	300 6	-2%		The Carlo Carlo	
feet to meaningly it					241				18 A
teritor redistribution		100							Earning group too. Epicore cores.

- RCTs, 20
- n, 1536

Onakpoya et al. Nutr Metabol Cardiovasc Dis 2014


Black Tea Lowers Blood Pressure and Wave Reflections after a Fat Load Challenge



- RCT XO
 - n, 19 H i
 - dose, 158 mg flavonoids

Grassi et al. Nutrients 2015

Chronic Black Tea Intake Reduces Blood Pressure



Hodgson et al. Arch Intern Med 2012

RCTs for Drugs vs. Nutrients:

• Drugs: short-term to show efficacy (<12 mo)

Follow-up for Disease Endpoint

• Nutrients: long-term (years)



の自然を	000 000 000	

	<u>HR</u>	<u>95% CI</u>	Pinteraction
CVD	0.91	0.82-1.02	NS
Myocardial infarction	0.98	0.74-1.06	NS
Total stroke	0.91	0.78-1.06	NS
Ischemic stroke	0.85	0.71-1.01	NS
CVD death	0.91	0.71-1.16	NS

Prospective cohort

- n, 37,193
- age, ≥45 y
 F/U, 16.2 y

Rautiainen et al. Am J Clin Nutr 2015

Effect of Multivitamins on Cardiovascular Disease Women's Health Study

	<u>HR</u>	<u>95% CI</u>	Pinteraction
CVD	0.91	0.82-1.02	NS
Myocardial infarction	0.98	0.74-1.06	NS
Total stroke	0.91	0.78-1.06	NS
Ischemic stroke	0.85	0.71-1.01	NS
CVD death	0.91	0.71-1.16	NS
CVD ≥70 y	0.72	0.48-1.08	0.04
CVD <3 serv F&V/d	0.77	0.55-1.09	0.01

Prospective cohort

- n, 37,193
- age, ≥45 y
- F/U, 16.2 y

Effect of Multivitamins on Cardiovascular Disease in Women

<u>Study</u>	<u>N</u>	CVD	<u>RR</u>	<u>F/U, y</u>	<u>Reference</u>
PC	21,132	MI	0.73	10.2	Rautiainen et al. AJCN 2010
CC	928	MI	0.66		Holmquist et al. J Nutr 2003
PC	80,082	CHD	0.76	14	Rimm et al. JAMA 1998
PC	381,553	IHD	0.82	7.0	Watkins et al. Am J Epi 2000
PC	381,553	Stroke	0.81	7.0	Watkins et al. Am J Epi 2000

PC, prospective cohort study CC, case control study


Rautiainen et al. Am J Clin Nutr 2015

3.

Effect of Multivitamins on Cardiovascular Disease in Men

Study	<u>N</u>	<u>CVD</u>	RR	<u>F/U, y</u>	<u>Ref.</u>
CC	2053	MI	0.79		Holmquist et al. J Nutr 2003
RCT	14,641	MI death	0.61	13.3	Sesso et al. JAMA 2012
PC	714,527	IHD	0.80	7.0	Watkins et al. Am J Epi 2000
Cohort (M&F)	77,719	CVD death	0.84	10.0	Pocobelli et al. Am J Epi 2009

Multivitamins Do Not Reduce the Risk of Cardiovascular Disease in Men: Physicians' Health Study II



RCT

- n, 14,641
- age, ≥50 y
 F/U, 13.3 y

Sesso et al. JAMA 2012

Multivitamins Do Reduce the Risk of Cardiovascular

Duration of Multivitamin Use							
	No use	<10 y	<u>10 – 20 y</u>	<u>≥20 y</u>	P _{trend}		
Cases	1293	211	67	18			
HR (95% CI)	1.00	0.94 (0.81-1.09)	0.91 (0.71-1.17)	0.56 (0.35-0.90)	0.05		


Cardiac revascularization: HR: 0.86 (0.76-0.98)


Prospective cohort

- n, 18,530
- age, ≥40 y

Rautiainen et al. J Nutr 2016

Multivitamins Reduce the Risk of Total Cancer Physicians' Health Study II





- n, 14,641
- age, ≥50 y
- F/U, 13.3 y

Gaziano et al. JAMA 2012

Is It Too Soon to Tell Men That Vitamins Prevent Cancer?

The PHS II study was a well-done, large-scale, blinded, randomized clinical trial with objective verification of cancer outcomes.

...the biological plausibility of the study hypothesis – that a multivitamin would be protective in a well-nourished population – is limited. This matters, because the chance that the study finding of a protective effect is true is intrinsically related (by Bayes theorem) to the plausibility of the hypothesis.

Bach and Lewis, JAMA 2012

Is It Too Soon to Tell Men That Vitamins Prevent Cancer?

...before drawing a definitive conclusion from this study that daily multivitamins reduce the risk of cancer in men, physicians and other readers must be convinced that the observed treatment effect is real and thus is likely to be reproduced in future experience, rather than a random event that is unlikely to recur.

Bach and Lewis. JAMA 2012

Is It Too Soon to Tell Men That Vitamins Prevent Cancer?

The marginal statistical significance and perplexing and somewhat counterintuitive nature of the study findings make drawing any firm conclusion premature.

Thus, it may be inappropriate to recommend that men take multivitamins to prevent cancer.


Bach and Lewis. JAMA 2012

39

RCTs for Drugs vs. Nutrients:


- Drugs: usually monotonic
- Nutrients: usually exhibit a threshold and are often under homeostatic control






40

Nutrient Thresholds for Health




41

Vitamin E Thresholds for Health



Implications of Nutrient Threshold Dose-Response Characteristics



Vitamin D and Calcium Supplementation
Do Not Prevent Fractures in Adults: Meta-analysis

USPSTF Recommendation Statement

...current is insufficient to assess the balance of the benefits and harms of combined vitamin D and calcium supplementation for the primary prevention of fractures in premenopausal women or in men.



Moyers et al. Ann Intern Med 2013

Vitamin D & Calcium Supplementation Do Prevent Hip Fractures in Women: Women's Health Initiative

- 2000 mg calcium + 400 IU vitamin D₃ or placebo
- 56% of the cohort took calcium + vitamin D before the trial
- Daily calcium intake during the RCT was 1135 mg/d in the placebo group and 2000 mg/d in the supplement group

RCT

- n, 36,282
- age, 50-79 y
- F/U, 7 y

Prentice et al. Osteoporos Intl 2013


Vitamin D & Calcium Supplementation Do Prevent Hip

- 2000 mg calcium + 400 IU vitamin D₃ or placebo
- 56% of the cohort took calcium + vitamin D before the trial
- Daily calcium intake during the RCT was 1135 mg/d in the placebo group and 2000 mg/d in the supplement group
- Among the women not taking calcium or vitamin D supplements at baseline, HR = 0.62 (95% CI: 0.38-1.00)


- n, 36,282
- age, 50-79 y
- F/U, 7 y

Prentice et al. Osteoporos Intl 2013

Multivitamin Slows Progression to Age-Related Macular Degeneration: Age-Related Eye Disease Study




AREDS Research Group. Arch Ophthalmol 2001



RCT

- n, 4,575
- age, 55-80 y
- F/U, 7 y

Lutein + Zexanthin in AREDS Formulation Reduces Risk of AMD Progression: AREDS II




- *Participants assigned to the control group were given the AREDS supplement, thus there is no true placebo group.
- n, 4,203
- age, 50-85 y
- F/U, 4.7

Chew et al. JAMA 2013

Predicted Plasma Lutein/Zeaxanthin Score Associated with Reduced Risk of Advanced AMD: Nurses' Health Study – Health Professionals F/U

Prospective cohorts

- n, 102,046
- age, 64 y
- F/U, 26 y



Wu et al. JAMA Ophthalmol 2015

RCTs for Drugs vs. Nutrients:

- Drugs: sick or high risk for disease
- · Nutrients: healthy or with moderate risk factors





RCTs of Nutrients in Primary Prevention

Cohort Considerations

- Health status
- Baseline nutrient intake and status
- Susceptibility to outcome
- Synergies with non-intervention nutrients

• Intervention Considerations

- Selection of nutrient/nutrient combinations
- Selection of form(s) and dose(s)
- Duration and follow-up periods
- Assessment of compliance


RCTs of Nutrients in Primary Prevention Physicians Health Study II

Baseline

 n, 261,248

 Respondents

 n, 112,160



Sesso et al. Control Clin Trials 2002


RCTs of Nutrients in Primary Prevention

Baseline

 n, 261,248

 Respondents


 n, 112,160




Sesso et al. Control Clin Trials 2002

Vitamins C and E Do Not Prevent Cardiovascular Disease in Men: *Physicians' Health Study II*

Vitamin E, 400 IU qod



Vitamin C, 500 mg/d



RCT

- n, 14,641
- age, ≥50 y
 F/U, 10 y
- Sesso et al. JAMA 2008

RCTs for Drugs vs. Nutrients: Adjuvants and Interactions

- **Drugs:** balance, complement, eliminate or exclude other drugs
- Nutrients: additive, antagonistic, synergistic interactions and drug-nutrient interactions are discounted

55

RCTs of Nutrients in Secondary Prevention

Percent of Subjects Receiving Drugs in the Vitamin E Group

<u>Drugs</u>	<u>HOPE</u>	HOPE 2
β-Blockers	39.9	40.2
Antiplatelet agents	77.0	76.7
Lipid lowering agents	28.4	28.3
Diuretics	15.7	15.2
Calcium channel blockers	47.2	46.7

Lonn et al. JAMA 2005

56

RCTs of Nutrients in Secondary Prevention

Percent of Subjects Receiving Drugs in the Vitamin E Group

<u>Drugs</u>	HOPP dimens HOPE 2
Drugs β-Blockers Antiplatelet agents Lipid lowering Diurgs medication/Polyph Diurgs medication/Polyph withdraw channel blockers	macy res
Antiplatelet agents	77.0
Lipid lowering ation Port	28.4 UNETHICAL!
Diuret medica	15.7
ithdraw channel blockers	47.2 46.7
N.	

Lonn et al. JAMA 2005

Prevention of Cardiovascular Disease & Cancer: An Evidence Review for the U.S. Preventative Serv	Updated Systematic	
RCT, 26 PC, 2 Fortman et al. Ann Intern Med 2013 CVD CVD Residue 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	icer 58	
Annals of Internal Medicine: Vitamin & Mineral Supp Prevention of Cardiovascular Disease & Cancer: An Evidence Review for the U.S. Preventative Serv The USPSTF concludes that the current evide insufficient to assess the balance of benefits the use of multivitamins for the prevention of disease or cancer.	Updated Systematic rices Task Force nce is and harms of	
Fortmann et al. <i>Arch Intern Med</i> 2013 Moyer et al. <i>Ann Intern Med</i> 2014	59	
Annals of Internal Medicine: Vitamin & Mineral Supp Prevention of Cardiovascular Disease & Cancer: An Evidence Review for the U.S. Preventative Serv	Updated Systematic	
The USPSTF concludes that the current evide insufficient to assess the balance of benefits the use of multivitamins for the prevention of disease or cancer. Our analysis has some limitations This is a ratudy design used primarily to evaluate drudesign might not be ideally suited to evaluate.	and harms of f cardiovascular eview of trials, g therapy. The	
Fortmann et al. <i>Arch Intern Med</i> 2013 Moyer et al. <i>Ann Intern Med</i> 2014	60	

Annals of Internal Medicine: Enough is Enough: Stop Wasting Money on Vitamins & Supplements	
The message is simple: Most supplements do not prevent chronic disease or death, their use is not justified, and they should be avoided.	
Antioxidants, folic acid, and B vitamins are harmful or ineffective for chronic disease prevention, and further large prevention trials are no longer justified.	
Guallar et al. Ann Intern Med 2013 61	
Annals of Internal Medicine: Enough is Enough: Stop Wasting Money on Vitamins & Supplements	
The case is closed – supplementing the diet of well- nourished adults with (most) mineral or vitamin supplements has no clear benefit and might even be	
harmful. These vitamins should not be used for chronic disease prevention. Enough is enough.	
Guallar et al. Ann Intern Med 2013 62	
How Much Cortainty is Nossessary	
How Much Certainty is Necessary?	
For drugs to treat disease: Balance of efficacy and toxicity in pharmacotherapy Comparative effectiveness with other drugs	
High cost	
For nutrients to prevent disease: Broad margin between efficacy and harm Substitution for essential nutrients not possible.	
 Substitution for essential nutrients not possible Overlapping action of dietary bioactive components Low cost 	
63	

Certainty vs. Confidence Level of confidence in a decision to act: • High benefit : risk ratio • Important consequences of Type II error · Low deployment cost · Low opportunity cost · Multiplicity of lines of evidence · Availability of ancillary measures Standards of Proof Remain Unchanged · Requiring RCT-level evidence when this design is ill-suited or not available impedes the application of nutrition research to public health issues • To fail to act due to absence of conclusive RCTs jeopardizes the potential for achieving benefits with little risk and low Nutrient-related decisions should be made at a level of certainty somewhat less than required for drugs **Conclusions** · To act in the absence of ultimate certainty requires a broad consideration of all research approaches along with revised estimates of the necessary certainty level and confidence needed to act in support of public health. • In assessing the balance between the potential harm of making or not making a recommendation, appropriate

educational strategies will be necessary to convey varying

levels of the strength of evidence.



Le mieux est l'ennemi du bien The perfect is the enemy of the good

- Voltaire (François-Marie Arouet) 1694-1778

6

Questions?

68

Credit Claiming

You must complete a brief evaluation of the program in order to obtain your certificate. The evaluation will be available for 1 year; you do not have to complete it today.

Credit Claiming Instructions:

- Go to www.CE.TodaysDietitian.com/NutritionStudies OR Log in to www.CE.TodaysDietitian.com and go to "My Courses" and click on the webinar title.
- 2. Click "Take Course" on the webinar description page.
- Select "Start/Resume Course" to complete and submit the evaluation.
- 4. Download and print your certificate.

Please Note: If you access the Evaluation between 3-4 pm ET on 12/1, you may experience a slow connection due to a high volume of users.

2	3
_	J